CD84 and B-cell chronic lymphocytic leukemia: SLAMF5 was previously reported to mediate the interactions between chronic lymphocytic leukemia (CLL) cells and their microenvironment30, leading to the support of CLL survival31 and to the suppression of T-cell activity via PD-L132.